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In clinical drug trials, it is appropriate to include as a 
covariate (a) any factor that is likely to diﬀ  erentially aﬀ  ect 
underlying rates of disease progression or (b) factors that 
are likely to diﬀ  erentially aﬀ  ect potential known mecha-
nisms of action of the drug being studied or (c) both. 
With regard to therapeutic drug trials in Alzheimer disease 
(AD), a frequent and appropriate concern is whether the 
apolipoprotein E (ApoE) genotype should be taken as a 
covariate in statistical analyses regarding eﬃ   cacy  or 
adverse eﬀ  ects.  Th  e ApoE ε4 genotype is the major 
genetic risk factor identiﬁ   ed for AD. Th  e ApoE ε4 
genotype is associated with earlier age of onset for the 
disease, with heterozygous patients having a 50% chance 
of dementia in their mid to late 70s and homozygous 
patients having a 50% chance of dementia in their mid to 
late 60s. Th   e odds ratio for developing dementia also goes 
up signiﬁ  cantly with gene dose. Th   ese associations hold 
true for both sporadic and familial forms of the illness. 
Pathologically, inheritance of the E4 genotype has been 
associated with greater total amyloid deposition in the 
brain, both in cortical plaques and in the vessels, and 
increased neuroﬁ  brillary tangles [1,2]. In mild cognitive 
impairment (MCI) or very-early-stage AD, the E4 
genotype is asso  ciated with greater deﬁ  cits on the New 
York Paragraph Recall test, Auditory-Verbal Learning 
Test, and Buschke test at baseline. On magnetic reso-
nance imaging, there are increases in both hippocampal 
atrophy and global atrophy at baseline [3], and on posi-
tron emission tomo  graphy using FDG (ﬂ  uorine-18-
ﬂ  uorodeoxy  glucose), there are greater deﬁ  cits in glucose 
metabolism in the posterior parietal and parahippo-
campal regions. In MCI subjects with the E4 genotype, 
cerebrospinal ﬂ   uid analyses typically have shown 
decreased levels of the protein amyloid beta (Aβ) 1-42 
and increased levels of Tau and pTau [4].
With regard to mechanisms of action with potential 
relevance to AD, the ApoE protein has been demon-
strated to have several functions, which include its roles 
as a major cholesterol-carrying protein in plasma and as 
the primary lipid-carrying transport protein in the 
central nervous system [5]. Th   e ApoE protein also func-
tions as a major transporter for the Aβ proteins [6]. Th  e 
ApoE2, E3, and E4 protein phenotypes have diﬀ  erential 
aﬃ     nities for lipids and Aβ and consequent variable 
eﬃ   ciencies in these transport roles. Th   ere is evidence in 
neuropathological studies of AD patients of greater 
microglial activation around Aβ plaques in patients with 
the ApoE 4 genotype [7]. Th   ese patients also demonstrate 
greater abnormal phosphorylation of Tau. In summary, 
the diﬀ   erent ApoE2, E3, and E4 genotypes code for 
diﬀ   erent ApoE protein phenotypes, which result in 
functional variation in the actions of this protein as it 
plays roles that virtually span known and theorized 
disease mechanisms involved in the pathogenesis or 
progression (or both) in AD.
With regard to the inﬂ  uence of the ApoE genotype on 
clinical factors of potential importance in AD clinical 
trials, there may be diﬀ  erential eﬀ  ects related to disease 
stage, trial length, and the speciﬁ  c eﬀ  ects of the drug 
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term biological progression of the disease. In the original 
12- to 26-week symptomatic trials of tacrine in mild to 
moderate AD, post hoc statistical analyses using the ApoE 
genotype to deﬁ  ne subgroups of patients suggested that 
patients with the ApoE4 genotype progressed more 
rapidly on placebo and conversely were more likely to 
respond to treatment with tacrine [8]. However, later 
studies looking at the ApoE genotype as a factor in other 
cholinesterase inhibitor trials in mild to moderate AD 
(donepezil, rivastigmine, and galantamine) failed to 
conﬁ  rm this hypothesized association [9-11].
Other short-term trials (6 weeks to 6 months) in mild- 
to moderate-stage AD with drugs believed to beneﬁ  cially 
aﬀ  ect mitochondrial function, energy metabolism, and/
or insulin resistance (caprylidene and rosiglitazone) were 
not positive overall, but subanalyses suggested that the 
subgroups with the ApoE2 or ApoE3 genotypes did 
signiﬁ  cantly  beneﬁ   t [12]. However, with rosiglitazone, 
three later double-blind placebo-controlled studies of 
1-year duration failed to reproduce or demonstrate bene-
ﬁ  cial eﬀ  ects in either the general AD population or the 
ApoE2 or ApoE3 genotype subgroups [13]. Overall, the 
inﬂ  uence of the ApoE genotype in shorter symptomatic 
studies in AD has been preliminary, negative, or equivocal.
Increased attention is being focused on an earlier stage 
of AD, MCI, in which several longer-duration trials have 
evaluated candidate drugs for delaying or preventing 
conversion from MCI to AD. Th  e ApoE genotype does 
appear to play a more signiﬁ  cant role in at least some of 
the longer MCI trials. In the Alzheimer Disease 
Cooperative Study group’s MCI double-blind placebo-
controlled trial (duration of 3 to 4 years) of donepezil or 
vitamin E versus placebo, MCI patients with the ApoE4 
genotype on placebo were much more likely to progress 
and convert to AD [14]. Patients with the ApoE4 geno-
type showed signiﬁ  cantly lower rates of conversion from 
MCI to AD versus placebo when treated with donepezil. 
Similar ﬁ  ndings were seen in a large comparably designed 
double-blind placebo-controlled trial of rivastigmine in 
MCI. Th  us, substantial evidence suggests that ApoE4-
related diﬀ  erences in brain and disease progression may 
be observed in association with ApoE4 in MCI and that 
these eﬀ   ects may diﬀ  erentially  inﬂ  uence  detectable 
treatment eﬀ  ects.
Th  e ApoE genotype also appears to have had diﬀ  er-
ential inﬂ   uence on adverse eﬀ   ects in a phase II AD 
treatment trial of a monoclonal antibody against Aβ 
(bapineuzumab). In this trial, subjects with the ApoE4 
genotype were much more likely to develop vasogenic 
brain edema at lower doses of this antibody [15]. Th  e 
known greater Aβ deposition in cerebral vasculature in 
AD patients with the ApoE4 genotype may or may not 
play a role in this phenomenon.
In summary, there is evidence that, through a variety of 
interactions and functional eﬀ  ects, variation in the ApoE 
genotype and the coded-for, diﬀ   erent resultant poly-
morphic proteins may aﬀ  ect rates of disease progression 
in AD and potentially responses to therapies (with regard 
to both eﬃ     cacy and safety). It therefore would seem 
prudent to stratify or include the ApoE genotype as a 
covariate in most AD therapeutic trials. Inclusion of the 
ApoE genotype should decrease variance in future 
studies, increasing the likelihood of successfully 
determining whether the drug under study beneﬁ  ts 
patients or is safe in treating AD.
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